Eflornithine oral - Orbus Therapeutics
Latest Information Update: 28 Nov 2025
At a glance
- Originator Orbus Therapeutics
- Class Antihyperglycaemics; Antineoplastics; Basic amino acids; Diamino amino acids; Small molecules
- Mechanism of Action Ornithine decarboxylase inhibitors
-
Orphan Drug Status
Yes - Anaplastic astrocytoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Anaplastic astrocytoma
- Phase I Glioblastoma
Most Recent Events
- 20 Nov 2025 Updated efficacy data from a phase III STELLAR trial in Astrocytoma released by Orbus Therapeutics
- 25 Nov 2024 Interim efficacy and adverse events data from a phase III STELLAR trial in Astrocytoma released by Orbus Therapeutics
- 26 May 2023 Phase-I clinical trials in Glioblastoma (First line therapy, Combination therapy) in USA (PO) (NCT05879367)